| Breast Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.94 |
| Advanced and Metastatic Breast Cancer |
0 |
0.83 |
| Radiation Therapy |
0 |
0.99 |
| Triple Negative Breast Cancer |
0 |
0.77 |
| Radiosurgery |
0 |
0.64 |
| Ovarian Cancer |
0 |
0.63 |
| Head and Neck Cancer |
0 |
0.55 |
| Genomic Medicine |
0 |
0.41 |
| Toxicology |
0 |
0.41 |
| Breast |
0 |
0.4 |
| Cancer |
0 |
0.38 |
| Antineoplastic Drug |
0 |
0.35 |
| Metastasis |
0 |
0.31 |
| Targeted Cancer Therapy |
0 |
0.29 |
| Brain Metastasis |
0 |
0.14 |
| Immunotherapy |
0 |
0.12 |
| Brain |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Hodgkin Lymphoma |
0 |
0.1 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.1 |
| Humanized Monoclonal Antibody |
0 |
0.08 |
| mTOR Inhibitor |
0 |
0.08 |
| Antibody Drug Conjugates |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |